Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000698548 | SCV000827216 | uncertain significance | Ataxia-telangiectasia syndrome | 2022-08-08 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ATM protein function. ClinVar contains an entry for this variant (Variation ID: 576129). This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 368 of the ATM protein (p.Gln368Glu). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV000763687 | SCV000894567 | uncertain significance | Familial cancer of breast; Ataxia-telangiectasia syndrome | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001557056 | SCV001778753 | uncertain significance | not provided | 2020-11-09 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Baylor Genetics | RCV004569350 | SCV005057177 | uncertain significance | Familial cancer of breast | 2023-12-01 | criteria provided, single submitter | clinical testing |